PepsiCo's GLP-1 Headache Deepens as Analysts Trim Targets Before Quarterly Update

Analysts cut PepsiCo price targets to $133-$150 ahead of results, citing GLP-1 drug demand risks, inflation, and North American volume weakness.

Wall Street's patience with PepsiCo is wearing thin. With the snack-and-beverage giant's quarterly results due imminently, a wave of analysts has moved to reset expectations — and the reasons go well beyond the usual pre-earnings caution.

At the heart of the concern is a question the food industry has been grappling with for months: what happens to demand for salty snacks and sugary sodas when a growing share of consumers is on appetite-suppressing medication? GLP-1 drugs have become a structural worry for makers of calorie-dense products, and PepsiCo sits squarely in their path. If shoppers cut back on chips and soft drinks, the company's traditional profit engines come under strain.

That anxiety is compounded by persistent inflation, which is visibly eroding consumer demand. Investors heading into the upcoming report are zeroing in on two pressure points: stubborn volume weakness across North America and the drag from elevated procurement costs.

A Cluster of Downgrades

The sell side has been busy. Wells Fargo's Chris Carey cut his price target to $135 from $140 on October 5, keeping an Equal Weight rating. A day earlier, UBS's Peter Grom trimmed his objective to $145 from $159 while standing by his Buy recommendation. Barclays had already moved on October 1, lowering its target to $133. Other houses have similarly scaled back their goals to levels spanning $133 to $150.

The subdued mood reflects a simple math problem: with a price-sensitive customer base, further price increases are becoming harder to push through. Shareholders are pressing for evidence that PepsiCo can hold its market share even as consumption patterns shift.

Margins Tell the Story

The operational strain was already visible in first-half figures. Adjusted operating margin came in at 16.3%, a decline of 15 basis points year over year. Management is countering rising costs with targeted price adjustments — roughly a week ago, plans emerged for increases on chips in the low-to-mid single-digit percentage range, though the new prices would remain below levels seen before earlier reductions. Similar moderate hikes on selected chips and sodas are reportedly under consideration.

Legal and Regulatory Crosscurrents

PepsiCo's international operations are generating their own friction. Together with Monster Beverage, the company has gone to court in India to challenge a ban by the country's food regulator on the use of the "Energy Drink" product designation. According to non-public court filings, the two firms argue that such labeling restrictions would meaningfully hamper their business activities.

On the domestic front, the FDA classified a voluntary recall of 122,021 cases of Gatorade across 37 states as Class II on October 2. The affected varieties contained undeclared color additives.

Meanwhile, the company is pushing ahead with distribution restructuring abroad. On Monday, Danish brewing group Carlsberg agreed to acquire Iberia Refreshments in Georgia and the JI Pepsi Cola Bottler Armenia from Revery, taking over production, sales and distribution of PepsiCo's soft drinks in both countries. Financial terms were not disclosed, and the Armenian transaction still requires regulatory approval.

Market Reaction

Trading has reflected the cautious backdrop. The stock changed hands at EUR 111.00 in today's session, up 0.5% on the day, though still well below its 52-week high of EUR 144.88. Earlier, pre-market quotes hovered at EUR 110.74 — close to the 52-week low of EUR 110.26. Year to date, the shares are down 9.7%.

For now, North American volumes remain the yardstick by which the strategy will be judged. Until it becomes clearer how deeply weight-loss injections are reshaping everyday eating habits, market participants are likely to keep a close watch on operating margin trends.